Literature DB >> 19654065

Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis.

Susanne Jacobsson1, Paula Mölling, Per Olcén.   

Abstract

The IgG antibody levels directed against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis, were examined in order to investigate the extent of natural immunisation against these antigens in different age groups. As a comparison, the IgG antibody levels against Haemophilus influenzae type b were examined. In the two youngest age groups, below 10 years of age, relatively low levels of both anti-fHbp and anti-NadA were measured. A 15-fold higher geometric mean concentration of anti-fHbp was noted in the age group 20-29 years as compared to the age group 15-19 years. The peak concentration was found at 30-39 years, followed by decreased levels with age. Anti-NadA showed a certain increase up to 9 years followed by an even increase up to 40-49 years.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19654065     DOI: 10.1016/j.vaccine.2009.07.056

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Vaccines, reverse vaccinology, and bacterial pathogenesis.

Authors:  Isabel Delany; Rino Rappuoli; Kate L Seib
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

2.  Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine.

Authors:  Luca Fagnocchi; Alessia Biolchi; Francesca Ferlicca; Giuseppe Boccadifuoco; Brunella Brunelli; Sébastien Brier; Nathalie Norais; Emiliano Chiarot; Giuliano Bensi; J Simon Kroll; Mariagrazia Pizza; John Donnelly; Marzia Monica Giuliani; Isabel Delany
Journal:  Infect Immun       Date:  2012-12-10       Impact factor: 3.441

3.  Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies.

Authors:  Kate L Seib; Brunella Brunelli; Barbara Brogioni; Emmanuelle Palumbo; Stefania Bambini; Alessandro Muzzi; Federica DiMarcello; Sara Marchi; Arie van der Ende; Beatrice Aricó; Silvana Savino; Maria Scarselli; Maurizio Comanducci; Rino Rappuoli; Marzia M Giuliani; Mariagrazia Pizza
Journal:  Infect Immun       Date:  2010-12-13       Impact factor: 3.441

Review 4.  Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease.

Authors:  Lisa K McNeil; Robert J Zagursky; Shuo L Lin; Ellen Murphy; Gary W Zlotnick; Susan K Hoiseth; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

5.  Structure of the C-terminal domain of Neisseria heparin binding antigen (NHBA), one of the main antigens of a novel vaccine against Neisseria meningitidis.

Authors:  Veronica Esposito; Valeria Musi; Cesira de Chiara; Daniele Veggi; Davide Serruto; Maria Scarselli; Geoff Kelly; Mariagrazia Pizza; Annalisa Pastore
Journal:  J Biol Chem       Date:  2011-09-29       Impact factor: 5.157

6.  Variation and molecular evolution of HmbR, the Neisseria meningitidis haemoglobin receptor.

Authors:  Nicholas J Evans; Odile B Harrison; Kirsten Clow; Jeremy P Derrick; Ian M Feavers; Martin C J Maiden
Journal:  Microbiology (Reading)       Date:  2010-02-11       Impact factor: 2.777

7.  Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine.

Authors:  Lisa K McNeil; Robert G K Donald; Alexey Gribenko; Roger French; Nathaniel Lambert; Shannon L Harris; Thomas R Jones; Sheng Li; Gary Zlotnick; Ulrich Vogel; Heike Claus; Raquel Abad; Julio A Vazquez; Ray Borrow; Jamie Findlow; Muhamed-Kheir Taha; Ala-Eddine Deghmane; Dominique A Caugant; Paula Kriz; Martin Musilek; Xin Wang; Jeni Vuong; Leonard W Mayer; Michael W Pride; Kathrin U Jansen; Annaliesa S Anderson
Journal:  mBio       Date:  2018-03-13       Impact factor: 7.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.